Noah M. Merin, MD, PhD, discusses the mechanisms of action and sequencing of oral therapies for chronic graft-vs-host disease (GVHD) in a live virtual event.
Noah M. Merin, MD, PhD
Advertisement
Assistant professor at Cedars-Sinai Medicine and medical director of the Hematology and Cellular Therapy Disease Research Group at the Cedars-Sinai Cancer Institute.
Articles by Noah M. Merin, MD, PhD
Noah M. Merin, MD, PhD, discusses approved therapies in acute and chronic graft-vs-host disease.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
